Ayman Al Saati

Dr. Ayman Al Saati

University Cancer Institute Toulouse Oncopole, Toulouse, Occitanie, France
+2
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAyman Al Saati
Ayman Al Saati
PPPierre Vande Perre
Pierre Vande Perre
JPJulien Plenecassagnes
Julien Plenecassagnes
JGJulia Gilhodes
Julia Gilhodes
NMNils Monselet
Nils Monselet
CTChristine Toulas
Christine Toulas
Even though male breast cancer (MBC) risk encompasses both genetic and environmental aetiologies, the primary risk factor is a germline pathogenic variant (PV) or likely pathogenic variant (LPV) in BRCA2, BRCA1 and/or PALB2 genes. To identify new potential MBC-specific predisposition genes, we sequenced a panel of 585 carcinogenesis genes in an MBC cohort without BRCA1/BRCA2/PALB2 PV/LPV. We identified 14 genes carrying rare PVs/LPVs in the MBC population versus noncancer non-Finnish European men, predominantly coding for DNA repair and maintenance of genomic stability proteins. We identified for the first time PVs/LPVs in PRCC (pre-mRNA processing), HOXA9 (transcription regulation), RECQL4 and WRN (maintenance of genomic stability) as well as in genes involved in other cellular processes. To study the specificity of this MBC PV/LPV profile, we examined whether variants in the same genes could be detected in a female breast cancer (FBC) cohort without BRCA1/BRCA2/PALB2 PV/LPV. Only 5/109 women (4.6%) carried a PV/LPV versus 18/85 men (21.2%) on these genes. FBC did not carry any PV/LPV on 11 of these genes. Although 5.9% of the MBC cohort carried PVs/LPVs in PALLD and ERCC2, neither of these genes were altered in our FBC cohort. Our data suggest that in addition to BRCA1/BRCA2/PALB2, other genes involved in DNA repair/maintenance or genomic stability as well as cell adhesion may form a specific MBC PV/LPV signature.

11 June 2025 in International Journal of Cancer
Verified
Journal Article
Open access
EKEdwige Kasper
Edwige Kasper
FBFlavie Boulouard
Flavie Boulouard
NBNoémie Basset
Noémie Basset
LGLisa Golmard
Lisa Golmard
HSHela Sassi
Hela Sassi
CHClaude Houdayer
Claude Houdayer
TP53 is included in most cancer predisposition multigene panels, especially those exploring Hereditary Breast and Ovarian Cancer (HBOC) predisposition. The purpose of this study was to define the contribution of TP53 pathogenic variants (PV) to the HBOC phenotype by collecting genotypes and phenotypes of 398 patients harboring a TP53 variant identified by 53,085 HBOC panel sequencing in 15 French laboratories. Heterozygous TP53 variants were identified in 0.44% of HBOC panels, evenly distributed between PV and VUS. Breast cancers associated with TP53 were predominantly triple positive, particularly Her2+ breast cancer, in situ cancer, or phyllodes tumors (p < 0.0001 for both). Interestingly, TP53 PV were identified across all ages in breast cancer patients, with enrichment before 36y. We demonstrated that null variants were linked with the HBOC phenotype, and missense variants, especially with a dominant negative effect, with the LFS phenotype (p = 0.0096). Patients with breast cancer harboring null variants displayed an earlier age of onset compared to missense (p = 0.0030). Surprisingly, we identified, in late‐onset cancer patients, TP53 hotspot PV usually identified in classic LFS, which underlines variable penetrance. Thus, this study suggests the existence of two phenotypic entities associated with TP53 PV: clinical LFS and TP53‐related breast cancer. The type of TP53 variant, as well as modifying factors reflected in family history, may influence these phenotypes, and both should be considered to define the clinical follow‐up of patients and relatives.

Verified
Journal Article
Open access
PDF file
PPPierre Vande Perre
Pierre Vande Perre
ASAyman Al Saati
Ayman Al Saati
BCBastien Cabarrou
Bastien Cabarrou
JPJulien Plenecassagnes
Julien Plenecassagnes
JGJulia Gilhodes
Julia Gilhodes
CTChristine Toulas
Christine Toulas
The majority of early-onset colorectal cancers (EOCRCs) are not substantiated by germline variants in the main CRC predisposition genes (the “DIGE” panel). To identify potentially novel EOCRC-specific predisposition genes, we analyzed 585 cancer pathway genes in an EOCRC patient cohort (n = 87, diagnosis ≤ 40 years, DIGE-), and compared their variant spectrum to the GnomAD cancer-free database. We identified high-impact variants (HVs) in 15 genes significantly over-represented in EOCRC. Among the 32 unrelated patients with a CRC family history (i.e., with a potentially dominant transmission pattern), 9 presented HVs in ten genes, four of which had a DNA repair function. We subsequently sequenced these 15 genes in a cohort of 82 late-onset CRCs (diagnosis ≥ 50 years, DIGE-) and found variants in 11 of these genes to be specific to EOCRC. We then screened these 11 genes in our patient database (n = 6482), which only contained 2% of EOCRCs (DIGE-), and identified two other EOCRC cases diagnosed after our cohort constitution, with HVs in RECQL4 and NUTM1. Altogether, we found that 37.5% and 18.75% of patients carrying heterozygous NUTM1 and RECQL4 HVs, respectively, in our database were diagnosed with EOCRC. Our work has identified a pattern of germline variants not previously associated with EOCRC.

9 April 2026
Verified
Thesis
Closed access
ASAyman Al Saati
Ayman Al Saati
Le cancer du sein chez l'homme (MBC, Male Breast Cancer) est une pathologie rare dont la physiopathologie est encore mal connue. Peu évoqué devant une symptomatologie mammaire, le diagnostic est souvent posé à un stade tumoral avancé, ce qui a pour conséquence un taux de survie globale plus faible chez l'homme que chez la femme. Le seul facteur de risque de MBC clairement identifié est la présence, au niveau constitutionnel, d'un variant pathogène ou probablement pathogène (" mutation ") sur les gènes BRCA2 et BRCA1 et, dans une moindre mesure, sur le gène PALB2. Les hommes atteints d'un cancer du sein bénéficient ainsi systématiquement d'une analyse génétique constitutionnelle, qui ne révèle la présence d'une mutation que dans 15 à 20 % des cas. Le but de ce travail de thèse était d'identifier de nouveaux facteurs de risque génétique au MBC. Pour cela, j'ai successivement constitué deux cohortes de patients porteurs de MBC vus en consultation à l'Oncopole de Toulouse et pour lesquels aucune mutation constitutionnelle n'a été identifiée sur les gènes analysés en routine : une première étude menée sur des données obtenues dans le cadre du diagnostic sur un panel de 585 gènes (n = 85 patients), puis une analyse en exome sur une plus grande cohorte (n = 122 patients). Les données génétiques issues du séquençage des patients atteints de MBC ont été comparées à celles d'une population contrôle indemne de cancer issue de la base de données GnomAD. Seuls les variants significativement plus présents dans la cohorte MBC par rapport à la population contrôle ont été retenus (p < 5 %). La première partie de mon travail a permis de mettre en évidence la présence de mutations dans des gènes codant pour des protéines impliquées dans le maintien de l'intégrité de l'ADN (BARD1, ERCC2, MRE11, etc.) mais également dans d'autres fonctions cellulaires comme la régulation transcriptionnelle (HOXA9) et la régulation du cycle cellulaire (CDKN2A) suggérant que des voies cellulaires, autres que celles de la réparation de l'ADN, pourraient être impliquées dans le risque de MBC (Al Saati et al., Int J Mol Sci. 2023, doi : 10.3390/ijms241814348). Cette première approche ne présentant pas l'exhaustivité nécessaire à l'étude globale du risque génétique lié à la prédisposition au MBC, j'ai ensuite élargi cette analyse génétique à l'ensemble des séquences codantes de l'ADN germinal (WES, Whole Exome Sequencing) au sein d'une cohorte de 122 patients. Dans cette étude, j'ai mis en évidence la présence de mutations dans des gènes impliqués dans diverses voies cellulaires : la réparation et le maintien de l'intégrité de l'ADN (comme déjà décrit dans la première phase du projet) mais également dans l'organisation du cilium et le transport transmembranaire (Al Saati et al., en préparation). J'ai également identifié la présence de mutations dans diverses voies métaboliques. Ces résultats suggèrent donc fortement que des voies cellulaires, en plus de celle de la réparation et du maintien de l'ADN, pourraient être impliquées dans le risque du MBC. Certains facteurs environnementaux ayant été impliqués dans le risque de MBC (exposition à certains toxiques, déséquilibre hormonal, obésité, etc.), le risque de MBC est donc très probablement lié à l'association de variants génétiques et de facteurs environnementaux. Ce travail va donc se poursuivre à travers l'essai MATADOR (Male breAsT cAncer preDisposition factOR) dont le but est de définir un profil de risque multifactoriel de MBC en associant les données génétiques acquises lors de ma thèse et des données environnementale et psychosociales. In fine, les résultats de ce projet permettront de déterminer, parmi les hommes exposés à des facteurs environnementaux et psychosociaux définis, lesquels présenteront un profil génétique à haut risque de développer un MBC et devraient donc bénéficier d'un programme de suivi préventif adapté.

12 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PPPierre Vande Perre
Pierre Vande Perre
ASAyman Al Saati
Ayman Al Saati
BCBastien Cabarrou
Bastien Cabarrou
JPJulien Plenecassagnes
Julien Plenecassagnes
JGJulia Gilhodes
Julia Gilhodes
CTChristine Toulas
Christine Toulas
Early-onset colorectal cancer (EOCRC) incidence is increasing rapidly worldwide. However, the majority of EOCRCs are not substantiated by germline variants in the main colorectal cancer (CRC) predisposition genes (the “DIGE” panel). To investigate a potential genetic transmission of EOCRC (dominant, recessive and oligogenic hypotheses) and thus identify potentially novel EOCRC-specific predisposition genes, we conducted an analysis of 585 cancer pathway genes on an EOCRC patient cohort (n=87 patients diagnosed at ≤ 40 years of age, DIGE-) with or without a CRC family history. By comparing this germline variant spectrum to the GnomAD cancer-free database, we identified high impact variants (HVs) in 15 genes significantly over-represented in the EOCRC cohort. Among the 32 unrelated patients with a CRC family history ( i.e. with a potentially dominant transmission pattern), nine presented HVs in ten of the genes tested, four of these genes had a DNA repair function. A potentially recessive transmission of EOCRC in patients without a CRC family history cannot be supported by our results nor can an oligogenic transmission. We subsequently sequenced these 15 genes in a cohort of 82 late-onset CRCs (cancer diagnosis ≥50 years, DIGE-) and found variants in 11 of these genes to be specific to EOCRC. To evaluate whether variants in these 11 genes would allow to specifically detect EOCRC patients, we screened our patient database (n=6482), which only contained 2% of EOCRCs (DIGE-), and identified two other EOCRC cases diagnosed after the constitution of our cohort, with individual HVs in RECQL4 and NUTM1 . Altogether, we showed that 37.5% and 18.75% of heterozygous NUTM1 and RECQL4 HVs of our database were diagnosed with EOCRC. Our work has identified a pattern of germline gene variants not previously associated with EOCRC. This paves the way to addressing the contribution of these variants to EOCRC risk and oncogenesis. Author Summary: Early-onset colorectal cancer (diagnosed at ≤ 40 years of age) is a rare disease that can in part be explained by a hereditary genetic predisposition. To identify novel gene variants potentially associated with EOCRC risk, we analysed a panel of 585 genes in 87 patients with early-onset colorectal cancer unexplained by conventional genetic tests. This first analysis highlighted 15 genes of interest. To evaluate if this genetic profile is specific to early onset, we sequenced these 15 genes in a population of late-onset colorectal cancers (diagnosed after 50 years of age). Variants in 11 of these genes were specific to the early-onset population. To assess if this genetic pattern allows to identify other early-onset cases, we screened these genes in our whole database of 6482 patients and identified two new early-onset cases. Our results need to be confirmed, and validated in larger cohorts but pave the way for future research into early-onset colorectal cancer and the possibility of improving screening or treatment options for these patients and their family members.